Full Press Release Details
[et_pb_section fb_built=”1″ _builder_version=”4.16″ custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_post_title author=”off” categories=”off” comments=”off” admin_label=”2025 American Association for Cancer Research (AACR) Annual Meeting – Poster Presentations” _builder_version=”4.27.4″ title_level=”h2″ title_text_color=”#0c71c3″ title_font_size=”28px” title_letter_spacing=”1px” title_line_height=”1.4em” meta_text_color=”#000000″ global_colors_info=”{}”][/et_pb_post_title][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” global_colors_info=”{}”]
Title: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors
Abstract: #1572 Session: PO.ET02.01 – Antibody-Based Cancer Therapeutics 1
Date & Time: Monday, April 28, 2025, 9:00 a.m. – 12:00 p.m. CT Presenter: Alice Yam, Ph.D., Vice President of Drug Discovery at Sutro Biopharma
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2025/04/2025-AACR-1572-STRO-004-preclinical-FINAL.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” global_colors_info=”{}”][/et_pb_button][et_pb_gallery gallery_ids=”16963″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” global_colors_info=”{}”][/et_pb_gallery][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” global_colors_info=”{}”]
Title: Enhancing Topo1i ADC efficacy: development of homogeneous dual-payload ADCs combining Topo1i with microtubule inhibitors or PARP inhibitors
Abstract: #2870 Session: PO.ET02.11 – Antibody-Based Cancer Therapeutics 2
Date & Time: Monday, April 28, 2025, 2:00 p.m. – 5:00 p.m. CT Presenter: Gang Yin, Ph.D., Vice President of Platform Engineering & Process Research at Sutro Biopharma
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2025/04/Sutro_AACR-2025-Dual-Payload-Poster-final.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” global_colors_info=”{}”][/et_pb_button][et_pb_gallery gallery_ids=”16961″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” global_colors_info=”{}”][/et_pb_gallery][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”19px” global_colors_info=”{}”]
Title: Anti-FRα antibody-drug conjugate luveltamab tazevibulin for the treatment of FRα-expressing non-small cell lung cancer
Abstract: #3299
Session: PO.CL01.09 – Predictive Biomarkers 4
Date & Time: Monday, April 28, 2028, 2:00 p.m. – 5:00 p.m. CT Presenter: Genevive Hernandez, Ph.D., Executive Director, Biomarker Research & Translational Science at Sutro Biopharma
[/et_pb_text][et_pb_button button_url=”https://www.sutrobio.com/wp-content/uploads/2025/04/2025-AACR-STRO-002-Poster-Final.pdf” url_new_window=”on” button_text=”Presentation” button_alignment=”left” admin_label=”Presentation – Button” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_size=”18px” button_text_color=”#0C71C3″ button_bg_color=”#FFFFFF” button_border_width=”1px” button_border_color=”#0C71C3″ button_border_radius=”3px” button_icon=”||divi||400″ button_icon_color=”#0C71C3″ button_on_hover=”off” global_colors_info=”{}”][/et_pb_button][et_pb_gallery gallery_ids=”16965″ fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” pagination_text_color=”#FFFFFF” module_alignment=”center” global_colors_info=”{}”][/et_pb_gallery][et_pb_divider color=”#0badbc” divider_weight=”2px” _builder_version=”4.16″ global_colors_info=”{}”][/et_pb_divider][/et_pb_column][/et_pb_row][/et_pb_section]